Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

Share :

SABCS 2017

5 - 9 Dec 2017
Published: 7 Dec 2017
Views: 1726
Rating:
Save
Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland

Prof Joensuu speaks at a SABCS 2017 press session about data from the phase III Synergism or Long Duration (SOLD) clinical trial.

Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment.

Read the news story for more.

Related Videos

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...
Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain
Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )
26 Mar 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
Remote genetic testing has the potential to increase the uptake of testing in...
Dr Bruce Montgomery - University of Washington, Seattle, USA
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )
31 Jan 2024
Genomic testing: Awareness and effective communication between healthcare...
Prof Richard Simcock and Antonella Cardone
Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )
22 Oct 2023
Advancing breast cancer treatment in Uganda by improving molecular testing
Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda
Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )
8 Jun 2023
Somatic mutation profile of breast cancer in Uganda
Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA
Somatic mutation profile of breast cancer in Uganda ( Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA )
8 Jun 2023
The current status of multiple myeloma diagnosis and treatment
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
24 May 2023
Breast cancer and survivorship
Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA
Breast cancer and survivorship ( Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA )
8 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation